NCT05713877View on ClinicalTrials.gov

Melatonin for Treatment of Delirium in Critically Ill Adult Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 1, 2023

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2025

Conditions
Delirium
Interventions
DRUG

Melatonin

Study drug will be given at 21:00 daily, starting on the day of enrolment until delirium resolution, hospital discharge, death, or up to 14 days. The study medication will be given by mouth (PO or per os) or, if needed, via the feeding tube.

DRUG

Placebo

Study drug will be given at 21:00 daily, starting on the day of enrolment until delirium resolution, hospital discharge, death, or up to 14 days. The study medication will be given by mouth (PO or per os) or, if needed, via the feeding tube.

Trial Locations (1)

H1T 2M4

RECRUITING

Hopital Maisonneuve-Rosemont, Montreal

All Listed Sponsors
collaborator

Maisonneuve-Rosemont Hospital

OTHER

lead

Ciusss de L'Est de l'Île de Montréal

OTHER